The Vanguard Group 13D and 13G filings for Apellis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 4:58 pm Purchase |
2023-12-29 | 13G | Apellis Pharmaceuticals, Inc. APLS |
The Vanguard Group | 9,555,678 8.060% |
343,187 (+3.73%) |
Filing |
| 2023-02-09 11:07 am Purchase |
2022-12-30 | 13G | Apellis Pharmaceuticals, Inc. APLS |
The Vanguard Group | 9,212,491 8.330% |
1,295,392 (+16.36%) |
Filing |
| 2022-02-09 3:24 pm Purchase |
2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
The Vanguard Group | 7,917,099 8.140% |
2,375,274 (+42.86%) |
Filing |
| 2021-02-10 10:30 am Purchase |
2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS |
The Vanguard Group | 5,541,825 7.320% |
5,541,825 (New Position) |
Filing |